{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:12:44Z","timestamp":1789708364596,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172604"],"award-info":[{"award-number":["82172604"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473199"],"award-info":[{"award-number":["82473199"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L244024"],"award-info":[{"award-number":["L244024"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.urolonc.2025.12.006","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T20:21:49Z","timestamp":1766866909000},"page":"110970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy"],"prefix":"10.1016","volume":"44","author":[{"given":"Mengnan","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhi","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9359-0975","authenticated-orcid":false,"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.12.006_bib0001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","article-title":"Progress in systemic therapy for advanced-stage urothelial carcinoma","volume":"21","author":"Nadal","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0002","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase \u2162 study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0003","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0004","doi-asserted-by":"crossref","first-page":"355","DOI":"10.6004\/jnccn.2020.7539","article-title":"Integration of immunotherapy into the treatment of advanced urothelial carcinoma","volume":"18","author":"Ghatalia","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0005","article-title":"Immunotherapy for advanced or metastatic urothelial carcinoma","author":"Maisch","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0006","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-022-01802-3","article-title":"Therapeutic landscape beyond immunotherapy in advanced urothelial carcinoma: moving past the checkpoint","volume":"82","author":"Tripathi","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0007","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European association of urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0008","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.3390\/cancers15194886","article-title":"Current and emerging strategies to treat urothelial carcinoma","volume":"15","author":"Rani","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0009","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0011","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0012","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0013","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0014","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0015","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0016","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0017","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-19-4162","article-title":"Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275","volume":"26","author":"Galsky","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0018","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0019","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/jama.2022.1816","article-title":"Causal directed acyclic graphs","volume":"327","author":"Lipsky","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0020","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","article-title":"Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial","volume":"25","author":"Hussain","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0021","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.24337","article-title":"A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma","volume":"115","author":"W\u00fclfing","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0022","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1\/2-positive metastatic bladder cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0023","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/College of American pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0024","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0026","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/cas.14681","article-title":"Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma","volume":"112","author":"Ye","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0027","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0028","doi-asserted-by":"crossref","first-page":"b2393","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"Brit Med J"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0029","first-page":"485","article-title":"Multiple imputation for nonresponse in surveys","volume":"26","author":"Rubin","year":"1989","journal-title":"J Mark Res"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0030","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0031","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"Brit Med J"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0032","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0033","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/10543406.2020.1757692","article-title":"The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring","volume":"30","author":"Dong","year":"2020","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0034","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1475-2840-9-38","article-title":"Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records","volume":"9","author":"Nishida","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0035","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.eururo.2019.07.032","article-title":"Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer","volume":"76","author":"Feld","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0036","article-title":"Axitinib versus sunitinib as first-line therapies for metastatic renal cell carcinoma: a multicenter retrospective analysis","volume":"37","author":"Hatakeyama","year":"2019","journal-title":"Genitourinary Cancers Symp"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","article-title":"Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect?","volume":"102","author":"Gerber","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0038","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0040","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1158\/0008-5472.CAN-09-1106","article-title":"Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation","volume":"69","author":"Tanaka","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0041","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"M\u00fcller","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0042","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0043","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1186\/s12885-023-11398-w","article-title":"The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy","volume":"23","author":"Tsai","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0044","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.006_bib0045","first-page":"665","article-title":"Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: updated efficacy and safety results from the phase II RC48-C017 trial","author":"Sheng","year":"2025","journal-title":"ASCO Genitourinary Cancers Symp"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T03:20:27Z","timestamp":1771903227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925004867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1078143925004867"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.006","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110970"}}